NIOX Group (LON:NIOX) Earns Buy Rating from Deutsche Bank Aktiengesellschaft

NIOX Group (LON:NIOX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday, MarketBeat reports. They currently have a GBX 90 ($1.20) price target on the stock. Deutsche Bank Aktiengesellschaft's price target indicates a potential upside of 53.13% from the company's current price.

Separately, Berenberg Bank reissued a "buy" rating and issued a GBX 90 ($1.20) price target on shares of NIOX Group in a research report on Tuesday, April 15th.

NIOX Group Stock Down 0.4 %

NIOX stock traded down GBX 0.23 ($0.00) during midday trading on Tuesday, reaching GBX 58.77 ($0.78). 261,593 shares of the company's stock traded hands, compared to its average volume of 1,104,655. NIOX Group has a 52 week low of GBX 53.40 ($0.71) and a 52 week high of GBX 80 ($1.06). The company has a market cap of £24.14 billion, a price-to-earnings ratio of 2,425.50 and a beta of 0.92. The firm's fifty day moving average price is GBX 65.48 and its 200-day moving average price is GBX 63.80. The company has a quick ratio of 1.94, a current ratio of 6.31 and a debt-to-equity ratio of 1.10.

NIOX Group (LON:NIOX - Get Free Report) last posted its earnings results on Tuesday, April 1st. The company reported GBX 2.27 ($0.03) earnings per share for the quarter. NIOX Group had a net margin of 28.21% and a return on equity of 13.29%. As a group, sell-side analysts forecast that NIOX Group will post 1.1658256 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Jonathan Emms purchased 127,454 shares of the firm's stock in a transaction dated Tuesday, April 1st. The stock was bought at an average price of GBX 8 ($0.11) per share, for a total transaction of £10,196.32 ($13,557.13). 46.72% of the stock is currently owned by corporate insiders.

About NIOX Group

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients.